 |
200 Diseases |  |
191 Trials |
|
191 Trials |  |
19915 News |  |
| «12...345678910111213...203204» |
- Cimzia (certolizumab pegol) / Astellas, UCB
PURIFIED MONOCLONAL RHEUMATOID FACTORS BIND FC CONTAINING TNF INHIBITORS IN VITRO BUT NOT THE FC-FREE TNF INHIBITOR, CERTOLIZUMAB PEGOL (Poster View) - Mar 29, 2024 - Abstract #EULAR2024EULAR_1509;
P4
The binding of ADA by the multivalent RF IgMs enabled formation of large protein complexes. These findings provide molecular insights into why patients with RA and high RF levels maintain higher drug concentrations and have better potential clinical outcomes when treated with CZP compared with ADA.
- Humira (adalimumab) / AbbVie
NEXT GENERATION SEQUENCING IDENTIFIES DIFFERENCES IN THE TRANSCRIPTOMIC PROFILE OF PRETREATMENT EARLY RHEUMATOID ARTHRITIS SYNOVIAL TISSUE FROM RESPONDERS AND NON RESPONDERS TARGETED TO ADALIMUMAB (Poster View) - Mar 29, 2024 - Abstract #EULAR2024EULAR_1505;
Treatment response may thus be more dependent on baseline ST gene expression rather than treatment choice. IHC of ST may be insufficient to identify the heterogeneity in RA ST and further in-depth characterisation may be required to fully comprehend the diversity of RA ST before treatment commences.
- Humira (adalimumab) / AbbVie
SAFETY OF BIOLOGIC THERAPY IN SOLID ORGAN TRANSPLANT RECIPIENTS WITH INFLAMMATORY DISEASE: REAL-WORLD EXPERIENCE FROM A TERTIARY CENTER IN ISRAEL (Poster View) - Mar 29, 2024 - Abstract #EULAR2024EULAR_1495;
Most patients continued the biologic therapy over 5 years, without evidence of opportunistic infections. Increased risk of infections should be weighted with administration of biologics in this highly immunosuppressed group of patients.
- GENETICALLY DEFINED SYSTEMIC AUTOINFLAMMATORY DISEASES IN PEDIATRIC PATIENTS WITH BEH (Poster Tour 5) - Mar 29, 2024 - Abstract #EULAR2024EULAR_1471;
Genetic evaluation of pediatric-onset BD is important as genetically defined SAID account for a substantial proportion of cases. Pediatric BD patients with SAID display greater levels of systemic inflammation and require more aggressive immunosuppressive therapy.
- sonelokimab (M1095) / Avillion, MoonLake Immunotherap
EFFICACY AND SAFETY OF SONELOKIMAB, A NOVEL IL-17A- AND IL-17F-INHIBITING NANOBODY (A2) - Mar 29, 2024 - Abstract #EULAR2024EULAR_1382;
P2
Patients were randomized (1:1:1:1:1) to sonelokimab 120 mg Q4W (with induction), sonelokimab 60 mg Q4W (with induction), sonelokimab 60 mg Q4W (no induction [NI]), placebo, or adalimumab (ADA) 40 mg Q2W (reference arm, not powered for statistical comparison); induction was Q2W until W8, and randomization was stratified by sex and prior biologic use. The 12-week ARGO Phase 2 trial dataset suggests that the IL-17A- and IL-17F-inhibiting Nanobody sonelokimab delivers rapid onset and robust levels of clinical response, including high-threshold outcomes, compared with placebo in patients with active PsA, with a favorable benefit
- Remicade (infliximab) / J&J, Enbrel (etanercept) / Pfizer, Amgen, Humira (adalimumab) / AbbVie
7-YEAR PERSISTENCE OF ANTI-TNF THERAPY IN PATIENTS WITH RHEUMATOID ARTHRITIS AND IMPACT ON DISEASE ACTIVITY (Poster View) - Mar 29, 2024 - Abstract #EULAR2024EULAR_1286;
These findings shows that under environment of a multidisciplinary care RA program the treatment persistence with anti-TNFs could be maintained long time during the course of the disease. Figure 1.
- Humira (adalimumab) / AbbVie
OMNIPRESENT POOR PROGNOSTIC FACTORS IN EARLY RHEUMATOID ARTHRITIS IN THE IMPROVED COHORT; IS EARLIER BDMARD TREATMENT ESCALATION NECESSARY FOR EVERYONE? (Poster View) - Mar 29, 2024 - Abstract #EULAR2024EULAR_1272;
High prevalence of PPFs is probably due to a large overlap between these PPFs and the 2010 RA classification criteria. According to current EULAR recommendations, it is recommended to start a b/tsDMARD in patients with PPF after failing first therapy with MTX and GC bridging.
- Humira (adalimumab) / AbbVie
ADALIMUMAB DOSE ESCALATION IN THE IMPROVED COHORT DOES NOT IMPROVE SHORT-TERM OUTCOMES (Poster View) - Mar 29, 2024 - Abstract #EULAR2024EULAR_1267;
Background: In rheumatoid arthritis (RA), anti-TNF dose escalation is reportedly applied in up to 10% of patients in real world settings.[1] Yet, clinical data on its efficacy are scarce and are limited mostly to dose variations in infliximab...If this was not achieved, patients received adalimumab (ADA) 40 mg/2 weeks with MTX, either immediately after a randomization step at t=4 months, or as delayed treatment at any treatment visit with DAS?1.6 in the other randomization arm, which constituted treatment with MTX + hydroxychloroquine + sulfasalazine + continued low dose prednisone (csDMARD combo)... In patients with early RA who did not achieve DAS remission on adalimumab 40 mg/2 weeks, we found no significant difference in clinical response between those who according to trial protocol doubled the ADA dose, and those who did not change the dose or even discontinued ADA as protocol violation.
- Actemra IV (tocilizumab) / Roche, JW Pharma, Idacio (adalimumab-aacf) / Fresenius Kabi, Humira (adalimumab) / AbbVie
CLINICAL OUTCOMES OF SWITCHING TO ADALIMUMAB BIOSIMILAR (MSB11022) IN PATIENTS WITH RHEUMATOID ARTHRITIS: RESTART SPANISH REGISTRY (Poster View) - Mar 29, 2024 - Abstract #EULAR2024EULAR_1249;
Table 1. Clinical outcomes after switching from original or other biosimilars to MSB11022 CCP: cyclic citrullinated peptides; CDAI: Clinical Disease Activity Index; DAS28-PCR: Disease Activity Score 28 for rheumatoid arthritis with C-reactive protein.
- Humira (adalimumab) / AbbVie
DRUG RETENTION OF TNFi BIOSIMILARS AND BIO-ORIGINALS IN DAILY RHEUMATOLOGY CARE IN GERMANY: INSIGHTS FROM THE RABBIT REGISTER (Poster View) - Mar 29, 2024 - Abstract #EULAR2024EULAR_1248;
These results are in line with the findings of other observational studies and strengthen the current perspective on the equivalence of BS with their BO. Possible limitations are the considerably lower numbers of treatment episodes in the BO groups compared to BS.
- Humira SC (adalimumab/hyaluronidase) / AbbVie, Humira (adalimumab) / AbbVie
EFFICACY AND SAFETY OF LOW OR HIGH DOSE METHOTREXATE IN COMBINATION WITH ADALIMUMAB IN PATIENTS WITH ELDERLY-ONSET RHEUMATOID ARTHRITIS: RESULTS FROM THE RANDOMISED, CONTROLLED MIRACLE TRIAL (Poster View) - Mar 29, 2024 - Abstract #EULAR2024EULAR_1236;
P4
When treated with methotrexate monotherapy, the EORA patients had higher efficacy with higher total polyglutamates concentrations despite lower methotrexate doses. When combined with adalimumab, the SDAI remission rate was not different with a tendency of inferior HAQ remission rate in the reduced dose of methotrexate group.
- Artlegia (olokizumab) - R / Pharm
EFFECT OF OLOKIZUMAB ON THE NEUTROPHIL-LYMPOCYTE RATIO IN PATIENTS WITH RHEUMATOID ARTHRITIS (Poster View) - Mar 29, 2024 - Abstract #EULAR2024EULAR_1234;
P3
Post hoc analysis of CREDO 1-3 showed an association of direct IL-6 blockade by olokizumab and NLR decrease, which was connected with the neutrophil component reduction. NLR changes correlated with changes in RA activity indices and laboratory parameters.
- Rinvoq (upadacitinib) / AbbVie, Humira (adalimumab) / AbbVie
ASSOCIATION OF EARLY REMISSION ON CLINICAL AND PATIENT-REPORTED OUTCOMES IN PATIENTS WITH RHEUMATOID ARTHRITIS: POST-HOC ANALYSIS OF DATA FROM THE SELECT-COMPARE STUDY (Poster View) - Mar 29, 2024 - Abstract #EULAR2024EULAR_1231;
P3
This post-hoc analysis demonstrated that patients with moderately to severely active RA and an inadequate response to MTX, who were treated with either UPA or ADA and achieved early remission, had less subsequent pain, and fatigue, as well as better physical function and physical QoL for at least 1 year vs patients who did not reach early remission. Thus, achieving remission early was associated with better health outcomes in patients with RA using targeted therapies.
- Rinvoq (upadacitinib) / AbbVie, Humira (adalimumab) / AbbVie
BENEFIT (Poster View) - Mar 29, 2024 - Abstract #EULAR2024EULAR_1227;
In both short- and long-term analyses, UPA 15 mg treatment led to comparable safety risks and better efficacy outcomes relative to ADA regardless of baseline CV risk status, except HZ which was higher with UPA. Thus, the overall benefit-risk profile was found to be favorable for UPA vs ADA independent of the risk groups, although the benefits were more apparent in younger patients without CV risk factors.
- tofacitinib / Generic mfg.
REAL-WORLD EFFECTIVENESS OF TOFACITINIB IN MONOTHERAPY OR IN COMBINATION WITH csDMARDs IN SUBGROUPS OF PATIENTS WITH RHEUMATOID ARTHRITIS: A COLLABORATION BETWEEN DUTCH REGISTRIES (TOFADUDAP STUDY) (Poster View) - Mar 29, 2024 - Abstract #EULAR2024EULAR_1212;
Older patients had lower drug survival independently of treatment group. ACPA status was not related to treatment effectiveness.
- Actemra IV (tocilizumab) / Roche, JW Pharma, Humira (adalimumab) / AbbVie, Rituxan (rituximab) / Roche
GLOBAL DISPARITIES IN BIOSIMILAR UPTAKE IN PATIENTS WITH RHEUMATOID ARTHRITIS (Poster View) - Mar 29, 2024 - Abstract #EULAR2024EULAR_1185;
In the included countries with lowest socioeconomic status, biosimilar uptake in 2022 was close to or equal to 0, which was in some cases explained by a total lack of availability. Whereas biosimilars are not by definition less costly than bio-originators for individual hospitals, the introduction of biosimilars does introduce price competition which lowers bDMARD prices in general.
- Comirnaty (tozinameran) / Pfizer, BioNTech
CELLULAR IMMUNE RESPONSE TO THE ANTI-SARS-CoV-2 BNT162b2 mRNA VACCINE IN PEDIATRIC AUTOIMMUNE INFLAMMATORY RHEUMATIC DISEASE PATIENTS AND CONTROLS (Poster Tour 2) - Mar 29, 2024 - Abstract #EULAR2024EULAR_1100;
Even though children with rheumatic inflammatory diseases are also being treated with immunomodulation and may have an underlying immune dysregulation, they did not show an increased breakthrough infection rate. This may support the importance of the cellular response in COVID-19 infections.
- Actemra IV (tocilizumab) / Roche, JW Pharma
TOCILIZUMAB VERSUS TUMOUR NECROSIS FACTOR INHIBITION IN POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS 36 MONTHS DATA ON EFFECTIVENESS AND SAFETY FROM A COMPARATIVE STUDY OF THE BIKER REGISTRY (Stolz 1) - Mar 29, 2024 - Abstract #EULAR2024EULAR_963;
TCZ was used predominantly as 2 nd line biologic. Higher rates of remission and minimal disease activity were observed in 1 st line compared to 2 nd line biologic users.
- Olumiant (baricitinib) / Eli Lilly, Humira (adalimumab) / AbbVie
ASSOCIATION BETWEEN PATIENT-REPORTED PAIN AND ACHIEVING REMISSION OR LOW DISEASE ACTIVITY AT 3 MONTHS IN PATIENTS WITH RHEUMATOID ARTHRITIS FROM THE RA-BE-REAL STUDY (Strauss 3) - Mar 29, 2024 - Abstract #EULAR2024EULAR_961;
Pts treated with BARI besides having longer disease duration and higher number of previous b/tsDMARDs are more likely to achieve pain control than pts receiving TNFi/OMA. Almost half the pts who achieved remission/LDA and who had BARI treatment achieved ?70% pain relief.
- Rinvoq (upadacitinib) / AbbVie, Humira (adalimumab) / AbbVie
DIRECT AND INDIRECT EFFECTS OF UPADACITINIB OR ADALIMUMAB ON PAIN IN RHEUMATOID ARTHRITIS: RESULTS FROM A RANDOMIZED PHASE 3 STUDY (Strauss 3) - Mar 29, 2024 - Abstract #EULAR2024EULAR_960;
Indirect effects on PtGA or TJC28 pain improvement were similar between UPA and ADA at all time points; however, direct effect on pain was up to two times greater with UPA vs ADA at weeks 12 and 26. These results suggest UPA may be more effective in control of pain, which may be due to either inflammatory or non-inflammatory mechanisms, than ADA in RA.
- Taltz (ixekizumab) / Eli Lilly, Japan Tobacco
EFFECT OF IXEKIZUMAB TREATMENT ON MRI STRUCTURAL LESIONS IN THE SACROILIAC JOINTS OF PATIENTS WITH RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS; A POST-HOC ANALYSIS OF A PLACEBO AND ACTIVE CONTROLLED RCT (A2) - Mar 29, 2024 - Abstract #EULAR2024EULAR_949;
P3
These results suggest UPA may be more effective in control of pain, which may be due to either inflammatory or non-inflammatory mechanisms, than ADA in RA. Objectives: This analysis evaluated the effect of IXE versus placebo and active control, adalimumab (ADA), on structural lesions in SIJ assessed by MRI at week 16 in bio-na
- COMPARATIVE ANALYSIS OF TUMOR NECROSIS FACTOR ALPHA INHIBITORS AND INTERLEUKIN 17 INHIBITORS IN PSORIATIC ARTHRITIS: EXPLORING CARDIOVASCULAR OUTCOMES (A2) - Mar 29, 2024 - Abstract #EULAR2024EULAR_947;
Objectives: This analysis evaluated the effect of IXE versus placebo and active control, adalimumab (ADA), on structural lesions in SIJ assessed by MRI at week 16 in bio-na Two cohorts were created: those receiving treatment with TNFi
- Orencia (abatacept) / BMS, Humira (adalimumab) / AbbVie
SUBCUTANEOUS ABATACEPT VS ADALIMUMAB HEAD-TO-HEAD COMPARISON IN ADULTS WITH EARLY, DUAL SEROPOSITIVE RHEUMATOID ARTHRITIS, POSITIVE FOR THE SHARED EPITOPE HLA CLASS II RISK ALLELES, AND AN INADEQUATE RESPONSE TO METHOTREXATE: RESULTS FROM THE PHASE 3 AMPLIFIED TRIAL (C9) - Mar 29, 2024 - Abstract #EULAR2024EULAR_901;
P3
Unlike results from a prior pilot study,[ 3 ] autoantibody and SE positivity did not confer an advantage in response to treatment with abatacept vs adalimumab in this study. Most patients with early RA tolerated and responded well to their assigned therapies.
- Orencia (abatacept) / BMS, Olumiant (baricitinib) / Eli Lilly
COMPARISON OF THE EFFECTS OF BARICITINIB AND ABATACEPT ON DISEASE ACTIVITY IN PATIENTS WITH RHEUMATOID ARTHRITIS: A PROPENSITY SCORE MATCHING ANALYSIS (Poster View) - Mar 29, 2024 - Abstract #EULAR2024EULAR_771;
Baricitinib significantly improved disease activity compared to abatacept within the 52-week observation period, especially in patients with previous use of b/tsDMARDs and those without concomitant use of MTX. Further studies are needed to investigate longer-term efficacy and safety.
- Humira (adalimumab) / AbbVie, Cosentyx (secukinumab) / Novartis
1,25(OH)2D3 REINFORCES IL-10 INDUCTION UNDER DUAL INHIBITION OF TNF? AND IL-17A IN CCR6+ MEMORY Th17 CELLS MEDIATED SYNOVIAL INFLAMMATION (Poster View) - Mar 29, 2024 - Abstract #EULAR2024EULAR_735;
and IL-17A showed not only suppression of the targeted proinflammatory cytokine(s) but also the induction of IL-10. This suggests a more comprehensive regulatory effect on T cell-derived synovitis which may be a promising therapeutic strategy to improve therapy in patients with inflammatory arthritis.
- Humira (adalimumab) / AbbVie
SUCCESSFUL THERAPEUTIC DRUG MONITORING BASED ADALIMUMAB DOSE REDUCTION IN RHEUMATOID ARTHRITIS PATIENT WITH LOW DISEASE ACTIVITY (ADDORA-LOW): A SINGLE BLIND, NON-INFERIORITY, RANDOMIZED CLINICAL TRIAL (Poster Tour 1) - Mar 29, 2024 - Abstract #EULAR2024EULAR_707;
This in turn reduces patients' burden of self-injections, potential risk of adverse events and costs, making this a more personalized, safe and effective strategy. Table 1.
- EX-VIVO ASSAY TO PREDICT PATIENT'S RESPONSE TO DIFFERENT TNFi DRUGS (Poster Tour 4) - Mar 29, 2024 - Abstract #EULAR2024EULAR_673;
We have developed an assay to predict response to TNFi in patients with rheumatic diseases. The assay may indicate whether a given patient may respond to a specific TNFi(s) or none of them, and identify differential suitability of the TNFi drugs in personalized manner.
- | Humira (adalimumab) / AbbVie
Journal: Extensive and deep granulomatous ulcers as an atypical manifestation of cartilage-hair hypoplasia syndrome: A diagnostic and therapeutic challenge. (Pubmed Central) - Mar 28, 2024
The patient was treated with anti-TNF-alpha adalimumab with partial improvement. Our case underscores the broad spectrum of clinical manifestations associated with cartilage hypoplasia syndrome and adds new evidence to the potential therapeutic efficacy of anti-TNF-alpha drugs in its treatment.
- ||| lutikizumab (ABT 981) / AbbVie
Enrollment open, Trial initiation date, Adverse events: A Study to Assess Adverse Events and Change in Disease Activity From Intravenous (IV) and Subcutaneous (SC) Lutikizumab in Adult Participants With Active Ulcerative Colitis (clinicaltrials.gov) - Mar 28, 2024
P2, N=200, Recruiting, Sponsor: AbbVie
Our case underscores the broad spectrum of clinical manifestations associated with cartilage hypoplasia syndrome and adds new evidence to the potential therapeutic efficacy of anti-TNF-alpha drugs in its treatment. Not yet recruiting --> Recruiting | Initiation date: Mar 2024 --> Oct 2024
- | Rinvoq (upadacitinib) / AbbVie, Humira (adalimumab) / AbbVie, Kevzara (sarilumab) / Asahi Kasei, Regeneron, Sanofi
Trial completion date, Trial initiation date, Trial primary completion date: Application of N-of-1 Rheumatoid Arthritis (clinicaltrials.gov) - Mar 27, 2024
P=N/A, N=18, Not yet recruiting, Sponsor: Tufts Medical Center
Not yet recruiting --> Recruiting | Initiation date: Mar 2024 --> Oct 2024 Trial completion date: Jan 2025 --> May 2025 | Initiation date: Jan 2024 --> May 2024 | Trial primary completion date: Jan 2025 --> May 2025
- || Clinical, Retrospective data, Review, Journal: Effectiveness and safety of biological and target synthetic drugs treatment for psoriatic arthritis: a systematic review with network meta-analysis. (Pubmed Central) - Mar 26, 2024
However, caution is necessary when interpreting the safety findings, as they are supported by evidence of low to very low certainty. Consequently, the balance between benefits and potential risks may change as new safety evaluation studies become available.
- | Humira (adalimumab) / AbbVie
Journal: Comparison between super-responders and non-super-responders in psoriasis under adalimumab treatment: a real-life cohort study on the effectiveness and drug survival over one-year. (Pubmed Central) - Mar 25, 2024
Super-responders treated with adalimumab have a higher rate of being female and fewer comorbidities. And super-responders have better PASI responses than non-super-responders, whether the patients were treated with adalimumab or switched to IL-17A inhibitors.
- | Remicade (infliximab) / J&J, Humira (adalimumab) / AbbVie
Journal: RATE OF INFECTION (TUBERCULOSIS) IN BRAZILIANS IBD PRIVATE PATIENTS: FOLLOW-UP 15 YEARS. (Pubmed Central) - Mar 25, 2024
The risk of biological therapy causing LTB is real, so patients with IBD should be continually monitored. This study reveals that the longer the exposure to anti-TNFs, the greater the risk.
- | tofacitinib / Generic mfg.
Preclinical, Journal: Long-term control of diabetes by tofacitinib-based immunosuppressive regimen after allo islet transplantation in diabetic rhesus monkeys that rejected previously transplanted porcine islets. (Pubmed Central) - Mar 23, 2024
The graft survival days of allo islets in these monkeys were >440, 395, >273, and 127, respectively, similar to that in allo islet transplanted cynomolgus monkeys that received the same immunosuppressive regimen without xeno sensitization. Taken together, it is likely that prior islet xenotransplantation does not affect the survival of subsequent allo islets under clinically applicable immunosuppressants.
- | Humira (adalimumab) / AbbVie
Journal: Case report: A case of resistant anti-SAE1 dermatomyositis with severe periorbital edema after hydroxychloroquine that responded to adalimumab. (Pubmed Central) - Mar 23, 2024
Taken together, it is likely that prior islet xenotransplantation does not affect the survival of subsequent allo islets under clinically applicable immunosuppressants. No abstract available
- || Clinical, Retrospective data, Review: Effects of tumor necrosis factor-alpha inhibitors on lipid profiles in patients with psoriasis: a systematic review and meta-analysis. (Pubmed Central) - Mar 23, 2024
Future prospective trials with long-term follow-up contribute to confirming and extending our findings. https://www.crd.york.ac.uk/PROSPERO/, identifier CRD42023469703.
- mycophenolate mofetil / Generic mfg.
IgA vasculitis (IgAV) due to TNF-? blockers in a patient with Crohn's disease: effect of mycophenolate mofetil (MMF) () - Mar 23, 2024 - Abstract #NKFSCM2024NKF_SCM_867;
Cessation of the biologic agent resolves the vasculitis but predisposes to flare of the IBD. Our patient had a long-term favorable outcome for both his IgAV and IBD with MMF, which has not previously been reported.
- || Remicade (infliximab) / J&J, Humira (adalimumab) / AbbVie
Biomarker, Review, Journal: Predictive biomarkers for anti-TNF alpha therapy in IBD patients. (Pubmed Central) - Mar 21, 2024
This review aims to present a comprehensive examination of predictive biomarkers for monitoring the therapeutic response to anti-TNF therapy in IBD patients. It will explore their limitations and clinical utilities, paving the way for a more personalized and effective therapeutic approach.
- || Remicade (infliximab) / J&J, Humira (adalimumab) / AbbVie
Biomarker, PK/PD data, Journal: Poor prognostic factors of pharmacokinetic origin predict outcomes in inflammatory bowel disease patients treated with anti-tumor necrosis factor-?. (Pubmed Central) - Mar 17, 2024
Implementation of proactive therapeutic drug monitoring reduced it, particularly during maintenance and in the presence of higher drug concentrations (p<0.001). We conclude that PPF of PK origin, including both higher Clearance and carriage of HLA DQA1*05, impact outcomes in patients with IBD.
- Osteoarthritis or Psoriatic Arthritis? (A7) - Mar 17, 2024 - Abstract #EULAR2024EULAR_508;
Previous treatments included sulfasalazine, methotrexate, adalimumab, etanercept, secukinumab, and ustekinumab.The hand arthralgia was constant, the lower back pain worse after periods of inactivity, and the neck pain worse on movement and associated with stiffness and crepitus.The patient was noted to be overweight with BMI of 29...For the first time, she now refers having mechanical thoraco-lumbar pain since she was at least 50 years old, not radiating, worsening after exercising (which she now increased) and improving with NSAID (Ibuprofen 600 mg) on demand.Complementary examinations results include HLA B27 negative test and serum acute phase reactants within normal range; imaging exams were requested and performed.Through this case we will discuss the challenges of differential diagnosis in PsA patients with spinal pain and the role of imaging exams.Case 3:Joe, a 65 years old male, was referred to the rheumatologic clinic in January 2024...His nails had a look that had never caught his attention, but nail pitting was clear. Laboratory tests showed a positive HLA B27, a negative rheumatoid factor, CRP 25 mg/L and ESR 46 mm/h.Through this case we will evaluate axial PsA as differential diagnosis at any age, and discuss clinical and imaging overlap with DISH.
- Difficult to Manage axSpA and PsA (A7) - Mar 17, 2024 - Abstract #EULAR2024EULAR_20;
Despite undergoing multiple treatments, including methotrexate, apremilast, secukinumab, ixekizumab, and adalimumab, her condition remained resistant...It presented as peripheral polyarthritis, enthesitis, and axial involvement.Given the success in managing her skin symptoms with risankizumab, Maria was then treated with another IL23 inhibitor, guselkumab, though it failed to alleviate her musculoskeletal symptoms...Transitioning to certolizumab 200 mg biweekly offered partial musculoskeletal relief but triggered a skin flare-up.Maria's treatment was then switched to bimekizumab, which cleared her skin...Due to the multiple failed treatment, it was decided, together with the patient to opt for an off-label approach through compassionate use: the addition of deucravacitinib to the ongoing treatment...Therapy with nonsteroidal anti-inflammatory drugs (NSAIDs) including ibuprofen and etoricoxib did not improve his symptoms...Despite, he still has a lot of pain and discomfort. The diagnosis and management of concomitant of fibromyalgia in axSpA will be discussed.
- | Omvoh (mirikizumab) / Eli Lilly
Journal: Mirikizumab (Omvoh) for ulcerative colitis. (Pubmed Central) - Mar 15, 2024
The diagnosis and management of concomitant of fibromyalgia in axSpA will be discussed. No abstract available
- | Humira (adalimumab) / AbbVie
Journal: Successful treatment of PASS syndrome with IVIG and anti-IL-1 treatment: A case report. (Pubmed Central) - Mar 15, 2024
Although there are no established treatment guidelines due to the rarity of these diseases, systemic corticosteroids, biologics, and immunosuppressive drugs are used currently. In our report, we presented a case of PASS syndrome who was unresponsive to adalimumab and in whom we observed improvement in both skin and joint manifestations with intravenous immunoglobulin (IVIG) and anti-IL-1 treatment.
- || Remicade (infliximab) / J&J, Entyvio (vedolizumab) / Takeda, Humira (adalimumab) / AbbVie
Retrospective data, Review, Journal: Efficacy of Biologics in the Treatment of Primary Sclerosing Cholangitis Associated With Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis. (Pubmed Central) - Mar 15, 2024
Notably, infliximab, adalimumab, vedolizumab, and tofacitinib showed ineffectiveness in reducing cholestatic markers. This review underscores the limited impact of biological and small-molecule therapies on disease progression in PSC-IBD patients, signifying the need for further exploration and development of treatment modalities in this domain.
- | Orencia (abatacept) / BMS, Humira (adalimumab) / AbbVie
Journal: Time to treat the climate and nature crisis as one indivisible global health emergency. (Pubmed Central) - Mar 15, 2024
This review underscores the limited impact of biological and small-molecule therapies on disease progression in PSC-IBD patients, signifying the need for further exploration and development of treatment modalities in this domain. No abstract available
- | Remicade (infliximab) / J&J, Humira (adalimumab) / AbbVie
Enrollment open: Comparison Between Infliximab and Adalimumab on Patients With Ulcerative Colitis (clinicaltrials.gov) - Mar 15, 2024
P=N/A, N=270, Recruiting, Sponsor: Vastra Gotaland Region
No abstract available Not yet recruiting --> Recruiting
- || Humira (adalimumab) / AbbVie, Tremfya (guselkumab) / J&J, Cosentyx (secukinumab) / Novartis
Clinical, Journal: Response Types and Factors Associated with Response Types to Biologic Therapies in Patients with Moderate-to-Severe Plaque Psoriasis from Two Randomized Clinical Trials. (Pubmed Central) - Mar 15, 2024
P3
Not yet recruiting --> Recruiting Early treatment response and baseline characteristics, including smoking, psoriasis duration, and obesity, may be associated with longer-term response to biologics.
- | Olumiant (baricitinib) / Incyte, Eli Lilly
Phase classification: RA-BRIDGE: A Study of Baricitinib (LY3009104) in Participants With Rheumatoid Arthritis (clinicaltrials.gov) - Mar 15, 2024
P4, N=2600, Active, not recruiting, Sponsor: Eli Lilly and Company
Early treatment response and baseline characteristics, including smoking, psoriasis duration, and obesity, may be associated with longer-term response to biologics. Phase classification: P3b/4 --> P4
- etrolizumab (RG7413) / Roche, vixarelimab (RG6536) / Roche, Humira (adalimumab) / AbbVie
ELEVATED OSM/OSMR EXPRESSION IN INFLAMED MUCOSAL TISSUE REFLECTS AN INFLAMMATORY CASCADE MEDIATED BY NEUTROPHIL:STROMAL INTERACTIONS ASSOCIATED WITH RESIDUAL DISEASE IN TREATMENT-REFRACTORY UC PATIENTS (102AB - Walter E. Washington Convention Center) - Mar 14, 2024 - Abstract #DDW2024DDW_8104;
P2
Blockade of OSMR to decrease pro-inflammatory mediators of inflammatory fibroblasts and dampen the inflammatory cycle in UC is a viable strategy for achieving benefits in clinical disease. Vixarelimab, an OSMR-targeted monoclonal antibody that blocks OSM/OSMR signaling, is currently in Ph2 clinical development for UC (NCT06137183).
- Stelara (ustekinumab) / J&J, Humira (adalimumab) / AbbVie, tesnatilimab (JNJ-64304500) / J&J
ARGESMAP: AN AI-DRIVEN MODEL TO ENHANCE ANATOMIC SEGMENT CLASSIFICATION OF GASTROINTESTINAL ENDOSCOPY VIDEOS IN CROHN'S DISEASE (Hall A, Poster Hall - Walter E. Washington Convention Center) - Mar 14, 2024 - Abstract #DDW2024DDW_7539;
P2b, P3b
This indicates that ArgesMAP has the potential to be integrated into clinical practice to identify and localize anatomic segments in CD videos, leading to improved diagnosis and treatment planning for patients with CD. Future work will investigate the generalization of anatomic segment classification to other types of Inflammatory Bowel Disease such as Ulcerative Colitis for novel endpoint development.